Axitinib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR1-3, PDGFRβ, and c-Kit. It inhibits VEGF-induced angiogenesis and reduces tumor growth in various xenograft models. Axitinib is clinically used for renal cell carcinoma treatment. Reagent grade, for research purpose.
Usually ships within 24 hours.